Amphastar Pharmaceuticals got a boost in its antitrust battle with Momenta Pharmaceuticals Inc. and Sandoz Inc. when it won a related patent infringement lawsuit brought against it by the two companies.
The victory in the infringement case over the method for testing an anticoagulant drug brings Amphastar a step closer to proving that Momenta and Sandoz engaged in anticompetitive conduct. Amphastar CEO Jack Zhang said in a March 20 statement that the company would seek a $100 million bond in the patent case and pursue further damages under a separate antitrust case that was given the green light by the ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.